

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW. WHO.INT

+41 22 791 3927 Tel. direct: Fax direct: +41 22 791 4836

E-mail: diagnostics@who.int

In reply please

CC/vl refer to:

Your reference: P17-370-9

Premier Medical Corporation Private Limited

Attention: Dr Rajeshkumar Patel Department of General Management

1304 Johnston Drive Watchung, New Jersey

07069

Etats Unis-d' Amerique

24 June 2019

Dear Dr Patel.

WHO Prequalification of In Vitro Diagnostics - Final Public Report Subject:

Product name: First Response® HIV 1+2/Syphilis Combo Card Test

Product codes: I20FRC25, I20FRC30, I20FRC50, I20FRC60 and I20FRC100

Regulatory version: Rest of World

Manufacturer: Premier Medical Corporation Private Limited

PQDx Reference Number: PQDx 0364-010-00

We are pleased to inform you that the above-referenced product was prequalified on 24 June 2019 and listed on the World Health Organization (WHO) list of prequalified in vitro diagnostic products.

The following post-prequalification activities are required to maintain the prequalification status:

- 1. Notification to WHO of any planned changes to a prequalified product, in accordance with "WHO procedure for changes to a WHO prequalified in vitro diagnostic" (document number PQDx 121); and
- 2. Post-market surveillance activities, in accordance with "WHO guidance on post-market surveillance of in vitro diagnostics" (ISBN 978 92 4 150921 3).

ENCL: as stated

You are also required to submit an annual report that details sales data and all categories of complaints in a summarized form. There are certain categories of complaints and changes to the product that must be notified immediately to WHO, as per the above-mentioned documents. The sales data will serve as denominator data to guide the frequency of re-inspection.

Failure to comply with any of the above-mentioned post-prequalification requirements may lead to remedial action by WHO, including but not limited to, de-listing from the WHO list of prequalified in vitro diagnostic products.

If you have any questions, please do not hesitate to contact us by email (diagnostics@who.int) or by telephone (+4122 791 3927).

Yours sincerely,

Mr Deus Mubangizi

Coordinator

Prequalification Team

Regulation of Medicines and other Health Technologies